An estimated 39 million Americans experience migraine, making it the third most common disease worldwide and a leading cause of disability in working-age adults. The condition is far more than a bad headache — migraine is a complex neurological disorder involving multiple phases, sensory changes, and often debilitating symptoms beyond head pain. The past decade has produced a revolution in migraine treatment with the first preventive medications designed specifically for migraine, transforming care for millions of patients.
This guide covers migraine phases, triggers, and current acute and preventive treatment options. For broader context, see our medical conditions resource hub.
When to seek emergency care: Call 911 or go to the ER for sudden severe “thunderclap” headache, headache with fever and stiff neck, headache with confusion or weakness, headache after head injury, or the worst headache of your life — these can indicate stroke, meningitis, or other serious conditions. New severe headache pattern after age 50 also warrants prompt evaluation.
What Migraine Is
Migraine is a primary headache disorder, meaning it is the disease itself rather than a symptom of another condition. It involves recurrent moderate to severe headaches with characteristic features: pulsating quality, often unilateral location, aggravation by routine physical activity, and accompanying symptoms like nausea, vomiting, or sensitivity to light and sound.
According to the National Institute of Neurological Disorders and Stroke, migraine prevalence in the US is approximately 12% — about 18% of women and 6% of men. Onset typically occurs in adolescence or young adulthood, with peak prevalence in the 30s and 40s.
The Four Phases
A migraine attack has up to four distinct phases, though not all patients experience all four.
Prodrome begins hours to days before the headache and includes mood changes, food cravings, neck stiffness, frequent yawning, and increased thirst. Many patients learn to recognize their personal prodrome and use it as an early treatment cue.
Aura affects roughly 25-30% of migraine patients. Most commonly visual — zigzag lines, blind spots, scintillating scotoma — auras can also include sensory symptoms (tingling spreading across one side), speech difficulty, or motor weakness (rare hemiplegic migraine). Aura typically lasts 20-60 minutes and most often precedes but sometimes accompanies the headache.
Headache typically lasts 4-72 hours untreated. Pain is moderate to severe, throbbing, often unilateral, and aggravated by movement. Photophobia, phonophobia, osmophobia (sensitivity to smells), nausea, and vomiting often accompany the pain. Postdrome follows resolution of headache and includes fatigue, cognitive fog, and mood changes lasting hours to a day.
Migraine Types
The two most common types are migraine without aura (about 75% of cases) and migraine with aura. Chronic migraine involves headache on 15 or more days per month, with at least 8 days meeting migraine criteria, for at least 3 months. About 1-2% of the US population has chronic migraine, often with substantial disability.
Less common variants include hemiplegic migraine (with motor weakness), retinal migraine (visual loss in one eye), vestibular migraine (dizziness as primary symptom), and migraine with brainstem aura. Per Mayo Clinic, accurate subtype identification influences treatment choice.
Common Triggers
Triggers vary by individual but common ones include hormonal changes (menstrual migraine affects up to 60% of women with migraine), specific foods (aged cheese, processed meats with nitrates, MSG, alcohol — particularly red wine), caffeine (both excessive use and withdrawal), stress, sleep changes (too much or too little), skipping meals, weather changes, strong sensory stimuli, and certain medications.
Identifying personal triggers through a headache diary helps many patients reduce attack frequency. However, trigger-avoidance has limits — over-restriction can become its own problem, and many attacks have no identifiable trigger.
Causes and Risk Factors
Migraine has substantial genetic contribution, with heritability estimates around 40-60%. Multiple genes affect migraine susceptibility through influences on cortical excitability, vascular regulation, and pain processing pathways. The trigeminovascular system and CGRP (calcitonin gene-related peptide) signaling are central to migraine pathophysiology, which has informed the development of newer treatments.
Risk factors include family history, female sex (3:1 ratio after puberty), depression and anxiety disorders, sleep disorders, and certain medical conditions. Migraine with aura is associated with modestly elevated stroke risk, particularly in women using estrogen-containing contraceptives or who smoke.
Diagnosis
Migraine is diagnosed clinically based on symptom pattern. The ICHD-3 (International Classification of Headache Disorders) criteria require specific characteristics including duration, pain features, and associated symptoms. Imaging is not required for typical migraine but may be obtained when red flags suggest secondary causes.
Red flags warranting imaging include sudden severe onset, age over 50 with new headaches, immunocompromise, history of cancer, neurologic deficits, fever, or progressive worsening. The “SNOOP” mnemonic helps identify concerning features.
Acute Treatment
For mild to moderate attacks, NSAIDs (ibuprofen, naproxen) and acetaminophen are often effective. Treating early in the attack improves response. Excedrin Migraine (acetaminophen, aspirin, caffeine) has FDA approval for migraine.
Triptans (sumatriptan, rizatriptan, eletriptan, others) have been first-line prescription acute medications since the 1990s, with response rates of 50-70%. They are contraindicated in patients with cardiovascular disease, stroke history, or uncontrolled hypertension. Generic sumatriptan tablets cost $5-$30 per tablet.
Newer options include gepants (ubrogepant, rimegepant, zavegepant nasal spray) — small-molecule CGRP antagonists with comparable efficacy to triptans without vascular contraindications. Ditans (lasmiditan) work through serotonin 5-HT1F receptors and offer another option for patients with cardiovascular concerns. Per Cleveland Clinic, antiemetics like metoclopramide help nausea and may have direct antimigraine effect.
Medication Overuse Headache
Frequent use of acute headache medications can paradoxically produce more headaches — medication overuse headache (MOH), also called rebound headache. Risk thresholds: triptans, ergots, opioids, or combination analgesics 10 or more days per month, or simple analgesics 15 or more days per month. Treating MOH typically requires a structured medication “wash-out” period plus initiation of preventive therapy.
Preventive Treatment
Preventive medication is recommended when attacks occur 4 or more days per month, when attacks are particularly severe or disabling, when acute medications are contraindicated or ineffective, or when there is risk of medication overuse.
Older preventive options include beta-blockers (propranolol, metoprolol), antiepileptic drugs (topiramate, valproate), tricyclic antidepressants (amitriptyline, nortriptyline), and venlafaxine. These are generic and inexpensive but have notable side effects and adherence challenges.
CGRP-targeted preventive therapies have transformed migraine care since 2018. Monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) given monthly or quarterly reduce monthly migraine days by 50% or more in roughly half of patients, with excellent tolerability. Oral CGRP receptor antagonists (atogepant, rimegepant) provide once-daily oral preventive options.
OnabotulinumtoxinA (Botox) has FDA approval specifically for chronic migraine, given as injections every 12 weeks at 31-39 sites. Response rates around 50% reduction in headache days are common. Costs run $1,000-$3,000 per treatment without insurance, though coverage is generally good for documented chronic migraine.
Lifestyle Approaches
Regular sleep schedule, consistent meal timing, hydration, regular aerobic exercise, and stress management all reduce migraine frequency in studies. Magnesium (400 mg daily), riboflavin (400 mg daily), and CoQ10 (300 mg daily) have modest evidence as preventive supplements.
Cognitive behavioral therapy and biofeedback have evidence-based roles, particularly for patients with high stress component or comorbid depression and anxiety. Neuromodulation devices — Cefaly (transcutaneous trigeminal nerve stimulation), gammaCore (vagus nerve stimulation), and Nerivio (remote electrical neuromodulation) — provide non-pharmacologic options.
When to See a Doctor
Recurrent moderate to severe headaches affecting work, school, or daily activities warrant evaluation. Primary care can initiate diagnosis and treatment for typical migraine; neurology — particularly headache specialists — handles refractory cases, chronic migraine, and complex variants. The American Migraine Foundation maintains a doctor finder.
Costs vary widely. Generic preventive medications run $5-$30 per month. CGRP monoclonal antibodies have list prices of $700-$1,000 per month, though manufacturer programs and most insurance reduce out-of-pocket significantly. Telehealth has substantially expanded migraine specialty access.
Frequently Asked Questions
What’s the difference between migraine and a regular headache?
Migraine is a specific neurological disorder with characteristic features — moderate to severe pain, often unilateral and pulsating, accompanied by nausea or sensitivity to light and sound, lasting 4-72 hours. Tension-type headache is typically bilateral, pressing rather than pulsating, and not associated with severe nausea or aggravation by movement.
Can migraines cause permanent damage?
Most migraines do not cause lasting brain damage, but migraine with aura is associated with modestly elevated stroke risk and small white matter lesions on MRI. Chronic migraine produces substantial functional disability. Effective treatment reduces both immediate suffering and these longer-term risks.
Are CGRP drugs safe long-term?
CGRP drugs have been on the market since 2018, and longer-term safety data continue to accumulate. Short and medium-term data suggest excellent tolerability with low rates of significant adverse effects. Long-term cardiovascular and immune safety remain under study but no significant signals have emerged.
Can migraines go away?
Migraine often follows a fluctuating course over decades. Many patients have less frequent attacks after age 50. Some women experience improvement after menopause; others worsen during perimenopause. Effective preventive treatment can produce sustained reduction in attack frequency, sometimes allowing eventual taper.
The Bottom Line
Migraine is a treatable neurological condition, and the toolkit has expanded dramatically with CGRP-targeted therapies. Effective management combines acute treatment for individual attacks with preventive strategies when frequency is high. Avoiding medication overuse, identifying personal triggers, and engaging with evidence-based lifestyle changes round out comprehensive care. If migraines are interfering with work, school, or daily life, evaluation by a primary care physician or headache specialist can open up significantly more effective options than over-the-counter pain relief alone.